Stada and Xbrane Get EU Approval for Lucentis Biosimilar for Eye Disease

The European Commission has granted a marketing authorization to Stada and Xbrane’s Ximluci (ranibizumab), a biosimilar of Novartis’ Lucentis (ranibizumab), to treat retinal vascular disorders.

Ximluci is an anti-vascular endothelial growth factor drug for treating wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion and visual impairment due to choroidal neovascularization in adults.

The companies jointly developed the product following a July 2018 collaboration and manufacturing agreement, but Stada holds the marketing authorizations and the commercial rights.